scholarly journals Salient features and outline of the joint Japanese guidelines for safe handling of cancer chemotherapy drugs

2017 ◽  
Vol 4 (4) ◽  
pp. 304 ◽  
Author(s):  
Kiyoko Kanda ◽  
Kazue Hirai ◽  
Keiko Iino ◽  
Hisanaga Nomura ◽  
Hisateru Yasui ◽  
...  
Keyword(s):  
Cancer Chemotherapy ◽  
Safe Handling ◽  
Chemotherapy Drugs ◽  
Salient Features ◽  
Japanese Guidelines

Selective Inhibitors of Histone Deacetylase 10 (HDAC-10)

2021 ◽  
Vol 28 ◽  
Author(s):  
Eftiola Pojani ◽  
Daniela Barlocco
Keyword(s):  
Histone Deacetylase ◽  
Cancer Chemotherapy ◽  
Chemotherapy Resistance ◽  
Hdac Inhibitors ◽  
Selective Inhibition ◽  
Epigenetic Mechanism ◽  
Inhibitory Potency ◽  
Chemotherapy Drugs ◽  
Hydrogen Bond Interactions ◽  
Class I Hdacs

: Histone acetylation balance is one epigenetic mechanism controlling gene expression associated with disease progression. It has been observed that histone deacetylase 10 (HDAC-10) isozyme contributes to the chemotherapy resistance; in addition, the poor clinical outcome observed in patients with aggressive solid tumors, such as neuroblastoma, has been associated with its overexpression. Moreover, HDAC-10 selective inhibition suppresses the autophagic response, thus providing an improved risk-benefit profile compared to cytotoxic cancer chemotherapy drugs. On these bases, HDAC-10 is becoming an emerging target for drug design. Due to the rapid progress in the development of next-generation HDAC inhibitors, this review article aims to provide an overview on novel selective or dual HDAC-8/10 inhibitors, as new leads for cancer chemotherapy, able to avoid the severe side-effects of several actual approved “pan” HDAC inhibitors. A literature search was conducted in MedLine, PubMed, Caplus, SciFinder Scholar databases from 2015 to the present. Since the disclosure that the HDAC-6 inhibitor Tubastatin A was able to bind HDAC-10 efficiently, several related analogues were synthesized and tested. Both tricyclic (25-30) and bicyclic (31-42) derivatives were considered. The best pharmacological profile was shown by 36 (HDAC-10 pIC50 = 8.4 and pIC50 towards Class I HDACs from 5.2–6.4). In parallel, based on the evidence that high levels of HDAC-8 are a marker of poor prognosis in neuroblastoma treatment, dual HDAC-8/10 inhibitors were designed. The hydroxamic acid TH34 (HDAC-8 and 10 IC50 = 1.9 µM and 7.7 µM, respectively) and the hybrid derivatives 46d, 46e and 46g were the most promising both in terms of potency and selectivity. Literature surveys indicate several structural requirements for inhibitory potency and selectivity towards HDAC-10, e.g., electrostatic and/or hydrogen bond interactions with E274 and complementarity to the P(E,A) CE motif helix.

'KNOWLEDGE REGARDING SAFE HANDLING OF CYTOTOXIC DRUGS AMONG STAFF NURSES WORKING IN SELECTED HOSPITALS, KAMRUP (METRO), ASSAM, WITH A VIEW TO DEVELOP AN INFORMATION BOOKLET: A DESCRIPTIVE STUDY'.

2021 ◽  
pp. 77-79
Author(s):  
Rupanylla Bareh ◽  
Mitali Barman
Keyword(s):  
Sampling Technique ◽  
Descriptive Study ◽  
Demographic Variables ◽  
Staff Nurses ◽  
Cytotoxic Drugs ◽  
Physical Contact ◽  
Safe Handling ◽  
Chemotherapy Drugs ◽  
Adequate Knowledge ◽  
Information Booklet

National Institute for Occupational Safety and Health (NIOSH), 2019 stated that about 8 million healthcare workers are potentially exposed to hazardous drugs in their workplace. Indian Council of Medical Research (ICMR), 2019 reported around 16.9% of nurses had their skin or eyes exposed to chemotherapy drugs. Widespread use of cytotoxic drugs in the treatment of cancer has led to higher health hazards among nurses who handle and administer such drugs, so nurses should know how to protect themselves from the effects of cytotoxic drugs by following safety measures during preparation, administration of cytotoxic drugs, cytotoxic waste disposal, cytotoxic spills and rationale use of PPE (Personal Protective Equipment) like mask, cap, two pairs of gloves, gown and shoe cover. Aim: The aim of the study was to assess the knowledge regarding safe handling of cytotoxic drugs among staff nurses working in selected hospitals, Kamrup(Metro), Assam. Methods And Materials: A quantitative descriptive study was conducted on safe handling of cytotoxic drugs among staff nurses.100 staff nurses who were working in selected hospitals, Kamrup (Metro), Assam and who fullled the inclusion criteria have been selected by using convenience sampling technique. The conceptual framework used in the study was based on modied Ludwig Von Bertalanffy (1968) general system theory. The tools used for the study were structured knowledge questionnaire to assess the knowledge regarding safe handling of cytotoxic drugs. Results: Data analysis was done by calculating mean, SD and chi-square test. It was found that majority i.e.56% of the staff nurses had moderate knowledge, 38% had adequate knowledge and 6% had inadequate knowledge. There was signicant association of knowledge with selected demographic variables like working area, physical contact towards cytotoxic drugs exposure and training attended on safe handling of cytotoxic drugs. However, there was no signicant association of knowledge with other demographic variables i.e. age, educational qualication, specialized oncology training, total years of working experience and total years of experience in specic working area. Conclusion: Through this study, the investigator concluded that staff nurses are moderately aware regarding safe handling of cytotoxic drugs. It was expected that all the staff nurses should have adequate knowledge on safe handling of cytotoxic drugs. An information booklet was provided to the staff nurses of selected hospitals and vigorous training should also be provided to the staff nurses inorder to update their body of knowledge.

Patients’ knowledge and awareness of safe handling of oral anticancer agents at Sultan Qaboos University Hospital in Oman

2021 ◽  
pp. 107815522110562
Author(s):  
Moataz M Hassan ◽  
Dhabya Al-Marzooq ◽  
Hanan Al-Habsi ◽  
Amna Al-Hashar ◽  
Murtadha Al-Khabori ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Anticancer Agents ◽  
Oral Chemotherapy ◽  
University Hospital ◽  
National Guidelines ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Safe Handling ◽  
Chemotherapy Drugs ◽  
Oral Anticancer Agents

Background Safe handling of oral anticancer agents is of great concern. There is a lack of clear, national guidelines on how patients can safely handle and dispose of unwanted medications. We aimed to evaluate the safe handling, storage, and disposal of oral anticancer drugs among cancer patients and caregivers at home. Method This cross-sectional survey of adult cancer patients (or their adult caregivers) used a closed-ended questionnaire from May 2019 to March 2020. Results A total of 257 patients (50 ± 15 years; range: 18–93 years) were enrolled; however, only 91% (233/257) reported self-administering oral anticancer medications. Caregivers were more likely to administer oral anticancer agents for patients ≥60 years than those <40 years old (63% vs. 8%; P = 0.001). Most patients (52%; 133/257) did not wash their hands after administering the drug; 74% (164/222) of the respondents reported that their medications were kept in a bedroom cabinet, while 18% (40/222) stored their medications in a refrigerator, and 5% (12/222) in a kitchen cabinet. A total of 55% (68/124) of patients returned their excess oral chemotherapy medications to the hospitals; however, 36% (45/124) disposed of their unused oral chemotherapy drugs in a household garbage container. Conclusion While two-thirds of patients stored their oral anticancer medications properly, more than half used inappropriate handling procedures. Disposal practices were inconsistent and did not adhere to the reported international guidelines.

How Medicare’s Payment Cuts For Cancer Chemotherapy Drugs Changed Patterns Of Treatment

2010 ◽  
Vol 29 (7) ◽  
pp. 1391-1399 ◽  
Author(s):  
Mireille Jacobson ◽  
Craig C. Earle ◽  
Mary Price ◽  
Joseph P. Newhouse
Keyword(s):  
Cancer Chemotherapy ◽  
Chemotherapy Drugs

scholarly journals Development and Evaluation of an e-Learning Module for Low- and Middle-Income Countries on the Safe Handling of Chemotherapy Drugs

2021 ◽  
Author(s):  
Sandrine von Grünigen ◽  
Berangère Dessane ◽  
Pauline Le Pape ◽  
Ludivine Falaschi ◽  
Antoine Geissbühler ◽  
...  
Keyword(s):  
Training Module ◽  
Middle Income ◽  
Participant Satisfaction ◽  
Safe Handling ◽  
Chemotherapy Drugs ◽  
Middle Income Countries ◽  
Learning Module ◽  
E Learning ◽  
Training Opportunities ◽  
Low And Middle Income

Abstract Despite the growing use of chemotherapy drugs in resource-constrained settings, training opportunities on safe handling practices are lacking. This study’s objectives were to develop and evaluate an e-learning training module on the safe handling of chemotherapy drugs to strengthen knowledge and practices in low- and middle-income countries (LMICs). The module’s curriculum was developed using the Six-Step Approach for Curriculum Development for Medical Education. Asynchronous, self-paced, e-learning lessons within the module were created and uploaded onto a free online platform, Pharm-Ed. The study ran online from January to April 2021. Participant recruitment was done using convenience sampling through various channels (social media, communities of practice). Training module effectiveness was evaluated using knowledge assessments (a pre-test and post-test study design) and participant satisfaction. We developed a comprehensive e-learning module on the safe handling of chemotherapy drugs comprising 11 asynchronous, self-paced, e-learning lessons. Eighty-two participants (68% pharmacists and 17% pharmacy students) from 17 countries completed at least one lesson, with a total of 259 lessons completed. Evaluation of the different lessons showed significant improvements in theoretical knowledge (p < 0.01) in all except one lesson and a high degree of participant satisfaction. As the use of anti-cancer drugs in LMICs will continue to increase, this e-learning module is an effective means to address the lack of training opportunities on the safe handling of chemotherapies for healthcare workers in these countries. The module could be integrated into a multi-modal approach aimed at reducing occupational exposure and increasing patient safety in cancer care centers.

The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior–like Symptoms in a Mouse Model of Cancer Chemotherapy–Related Symptoms

2006 ◽  
Vol 8 (2) ◽  
pp. 157-169 ◽  
Author(s):  
Lisa J. Wood ◽  
Lillian M. Nail ◽  
Nancy A. Perrin ◽  
Collin R. Elsea ◽  
April Fischer ◽  
...  
Keyword(s):  
P38 Mapk ◽  
Inflammatory Cytokines ◽  
Cancer Chemotherapy ◽  
Cytokine Production ◽  
Sickness Behavior ◽  
Dependent Manner ◽  
Murine Macrophages ◽  
Chemotherapy Drug ◽  
Chemotherapy Drugs ◽  
Tnf Α

Cancer chemotherapy–related symptoms such as fatigue, malaise, loss of interest in social activities, difficulty concentrating, and changes in sleep patterns can lead to treatment delays, dose reductions, or termination and have a profound effect on the physical, psychosocial, and economic aspects of quality of life. Clinicians have long suspected that these symptoms are similar to those associated with “sickness behavior,” which is triggered by the production of the inflammatory cytokines IL-1β, TNF-α, and IL-6 by macrophages and other cells of the innate immune system in response to immune challenge. The p38 mitogen-activated protein kinase (p38 MAPK) plays a central role in the production of these cytokines and consequently the induction of sickness behavior. Several cancer chemotherapy drugs have been shown to activate p38 MAPK, but whether these drugs can also induce the production of inflammatory cytokines to cause sickness behavior is unknown. The aim of this study was to determine whether the cancer chemotherapy drug etoposide (VP-16), which is known to activate p38 MAPK, could induce inflammatory cytokine production by murine macrophages and sickness-like behaviors when injected into mice. VP-16 activated p38 MAPK and induced IL-6 production in murine macrophages in a p38 MAPK– dependent manner. VP-16 administration rapidly increased serum levels of IL-6 in healthy mice and induced sickness-like behaviors as evidenced by a decrease in food intake, body weight, hemoglobin level, and voluntary wheel-running activity. These findings support the idea that the induction of IL-1β, TNF-α, and IL-6 by cancer chemotherapy drugs underlies the fatigue and associated symptoms experienced by people undergoing cancer chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document